Non-HIV-related kaposi sarcoma in BRAFi-treated patient

Non-HIV-related kaposi sarcoma in BRAFi-treated patient

(HealthDay)—In a case report published online Feb. 28 in the Journal of Clinical Pharmacy and Therapeutics, researchers document non-HIV-associated Kaposi sarcoma in a male patient with myasthenia gravis and metastatic melanoma treated with the BRAF inhibitor dabrafenib.

Sagun Parakh, M.B.Ch.B., from Austin Health in Heidelberg, Australia, and colleagues describe a case of extensive bilateral pedal Kaposi sarcoma in a patient treated with dabrafenib for metastatic melanoma. The 76-year-old, HIV-negative, male patient, without diabetes, with a history of and presented with enlarging macular/plaque-like rash on his feet. The rash was preceded by bilateral plantar shooting pains.

The authors initially thought that the rash was due to initiation of the BRAF inhibitor dabrafenib, as rash progression was in the context of acute-on-chronic immunosuppression. Kaposi sarcoma was revealed in histopathologic findings from skin biopsies. The patient continued on dabrafenib and was treated with superficial radiotherapy to the feet, which resulted in prompt pain relief and arrest of further spread of Kaposi sarcoma.

"This case illustrates the diagnostic pitfalls in patients treated with targeted therapies and highlights the importance of broad differentials for unusual presentations and early biopsy," the authors write.

Explore further

Factors ID'd for MAPK treatment outcome in melanoma

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Non-HIV-related kaposi sarcoma in BRAFi-treated patient (2016, March 17) retrieved 11 August 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments